AZ-1355
AZ-1355 is an orally active and effctive lipid-lowering agent. AZ-1355 inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro[1].
Product Specifications
CAS Number
[75451-07-9]
UNSPSC
12352005
Target
Prostaglandin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Endocrinology; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/AZ-1355.html
Purity
98.19
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC=C2OC3=C(OC)C=CC=C3CNC2=C1)OCC
Molecular Formula
C17H17NO4
Molecular Weight
299.32
References & Citations
[1]Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40 (3-4) :263-71.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-101692/AZ-1355-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-101692/AZ-1355-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IP; TXA2/TP
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ETHE1, CT (Protein ETHE1, Mitochondrial, Ethylmalonic Encephalopathy Protein 1, Hepatoma Subtracted Clone One Protein, HSCO) (MaxLight 750)
ETHE1, CT (Protein ETHE1, Mitochondrial, Ethylmalonic Encephalopathy Protein 1, Hepatoma Subtracted Clone One Protein, HSCO) (MaxLight 750)
